5. References
- American Association for the Study of Liver Diseases. HCV guidance: recommendations for testing, managing, and treating Hepatitis C. Updated 2023. Accessed June 14, 2024. https://www.hcvguidelines.org/
- Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc; 2024. Available at: http://www.clinicalpharmacology.com. Accessed June 14, 2024.
- Ribavirin oral capsules package insert. Aurobindo Pharma Limited. July 2023.
- Elbasvir/grazoprevir (Zepatier) package insert. Merck Sharp & Dohme, LLC. May 2022.
- Glecaprevir/pibrentasvir (Mavyret™) package insert. AbbVie Inc. October 2023.
- Ledipasvir and sofosbuvir (Harvoni) package insert. Gilead Sciences, Inc. March 2020.
- Sofosbuvir/velpatasvir (Epclusa) package insert. Gilead Sciences, Inc. April 2022.
- Sofosbuvir (Sovaldi) package insert. Gilead Sciences, Inc. March 2020.
- Peginterferon alfa-2A (Pegasys) package insert. Pharmaand GmbH. December 2023.
- Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) package insert. Gilead Sciences, Inc. November 2019.
- Bhattacharya D, Aronsohn A, Price J, Lo Re V. The American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel , Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America recommendations for testing, managing, and treating Hepatitis C Virus infection, Clin Infect Dis, 2023;, ciad319, https://doi.org/10.1093/cid/ciad319.